| No remission* | Discontinuation due to remission | p value | |
|---|---|---|---|
| N=3,102 | N=59 | ||
| Mean age (years ± SD) | 53.9±13.2 | 58.5±12.4 | 0.007 |
| Sex (female %) | 79.9 | 88.1 | 0.11 |
| Mean disease duration (years ± SD) | 9.3±8.7 | 7.0±6.0 | 0.04 |
| Seropositive RA (%) | 89.3 | 89.8 | 0.89 |
| Current smoking | 12.2 | 6.8 | 0.20 |
| Extra-articular disease (%) | 20.1 | 15.3 | 0.35 |
| Nodular disease (%) | 7.4 | 5.1 | 0.25 |
| Mean DAS-28 ± SD | 3.75±2.85 | 4.22±2.47 | 0.21 |
| Methotrexate (ever, %) | 56.7 | 62.7 | 0.35 |
| Steroids use (at index date, %) | 53.4 | 59.3 | 0.37 |
| DMARDs use (at index date, %) | 71.2 | 71.2 | 0.99 |
| Anti-TNF therapy (as first treatment, %) | 93.9 | 98.3 | 0.15 |
↵* Included all patients censored and those still receiving biologic DMARDs.